{
    "ticker": "FRTX",
    "name": "Forte Biosciences, Inc.",
    "description": "Forte Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for patients with rare and severe dermatological conditions. Founded in 2017 and headquartered in New York, Forte is dedicated to addressing unmet medical needs through its proprietary technology platforms. The company is primarily known for its lead product candidate, FB-401, which is being developed as a treatment for patients with atopic dermatitis, a chronic skin condition characterized by inflammation and irritation. Forte's approach is rooted in its unique formulation that aims to restore skin barrier function and alleviate symptoms associated with dermatological diseases. The company emphasizes a patient-centric philosophy, ensuring that its research and development efforts are guided by the needs and experiences of patients and their families. Forte is also exploring additional therapeutic areas and expanding its pipeline to include treatments for other skin disorders. With a strong commitment to scientific excellence, Forte Biosciences is actively engaged in clinical trials and partnerships to advance its mission of improving the quality of life for individuals suffering from severe skin conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2017",
    "website": "https://www.fortebiosciences.com",
    "ceo": "Paul D. Dorman",
    "social_media": {
        "twitter": "https://twitter.com/fortebio",
        "linkedin": "https://www.linkedin.com/company/forte-biosciences-inc/"
    },
    "investor_relations": "https://www.fortebiosciences.com/investor-relations",
    "key_executives": [
        {
            "name": "Paul D. Dorman",
            "position": "CEO"
        },
        {
            "name": "Michael A. Dorman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Dermatology Products",
            "products": [
                "FB-401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Forte Biosciences, Inc. | Innovative Dermatology Solutions",
        "meta_description": "Forte Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for severe dermatological conditions. Learn about our mission and pipeline.",
        "keywords": [
            "Forte Biosciences",
            "Biotechnology",
            "Dermatology",
            "Atopic Dermatitis",
            "Skin Conditions"
        ]
    },
    "faq": [
        {
            "question": "What does Forte Biosciences focus on?",
            "answer": "Forte Biosciences focuses on developing innovative therapies for rare and severe dermatological conditions."
        },
        {
            "question": "Who is the CEO of Forte Biosciences?",
            "answer": "Paul D. Dorman is the CEO of Forte Biosciences, Inc."
        },
        {
            "question": "Where is Forte Biosciences headquartered?",
            "answer": "Forte Biosciences is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Forte's lead product candidate?",
            "answer": "Forte's lead product candidate is FB-401, aimed at treating atopic dermatitis."
        },
        {
            "question": "When was Forte Biosciences founded?",
            "answer": "Forte Biosciences was founded in 2017."
        }
    ],
    "competitors": [
        "VRTX",
        "REGN",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "PFE"
    ]
}